Navigation Links
Sangamo BioSciences Announces Presentation at the 18th Annual Newsmakers in the Biotech Industry Conference
Date:10/14/2011

RICHMOND, Calif., Oct. 14, 2011 /PRNewswire/ -- Sangamo BioSciences, Inc. (Nasdaq: SGMO) announced today that Edward Lanphier, Sangamo's president and CEO, will provide an update on the progress of Sangamo's ZFP Therapeutic® development programs and an overview of the company's business strategy at 9:30 am ET on Friday, October 21, 2011 at the 18th Annual Newsmakers in the Biotech Industry Conference which will be held in New York City.

The presentation will be webcast live and may be accessed via a link on the Sangamo BioSciences website in the Investor Relations section http://investor.sangamo.com/index.cfm under Events and Presentations. The presentation will be archived on the Sangamo website for two weeks after the event.

About Sangamo

Sangamo BioSciences, Inc. is focused on research and development of novel DNA-binding proteins for therapeutic gene regulation and modification. Sangamo has a Phase 1/2 clinical trial and two ongoing Phase 1 clinical trials to evaluate safety and clinical effect of a treatment for HIV/AIDS as well as a Phase 1 trial of a treatment for recurrent glioblastoma multiforme. Other therapeutic development programs are focused on Parkinson's disease, monogenic diseases, neuropathic pain and nerve regeneration.  Sangamo's core competencies enable the engineering of a class of DNA-binding proteins called zinc finger DNA-binding proteins (ZFPs).  By engineering ZFPs that recognize a specific DNA sequence, Sangamo has created ZFP transcription factors (ZFP TFs) that can control gene expression and, consequently, cell function.  Sangamo is also developing sequence-specific ZFP Nucleases (ZFNs) for gene modification.  Sangamo has established strategic partnerships with companies in non-therapeutic applications of its technology including Dow AgroSciences and Sigma-Aldrich Corporation. For more information about Sangamo, visit the company's website at www.sangamo.com.

ZFP Therapeutic® is a registered trademark of Sangamo BioSciences, Inc.


'/>"/>
SOURCE Sangamo BioSciences, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Sangamo BioSciences Announces Presentation at the 2011 UBS Global Life Sciences Conference
2. Sangamo BioSciences Reports Second Quarter 2011 Financial Results
3. Sangamo BioSciences Announces Efficient Generation of Transgenic Pigs Using Zinc Finger Nuclease (ZFN) Technology
4. Sangamo BioSciences Announces Second Quarter 2011 Conference Call and Webcast
5. Sangamo BioSciences Announces Presentation at Two Upcoming Investor Conferences
6. Sangamo Announces Pricing of Public Offering of Common Stock
7. Sangamo Announces Public Offering of Common Stock
8. Sangamo BioSciences and CHDI Foundation Announce Collaboration to Develop ZFP Therapeutic® for Huntingtons Disease
9. Sangamo BioSciences Announces Presentation at the 10th Annual Needham Healthcare Conference
10. Sangamo BioSciences Reports Fourth Quarter and Full Year 2010 Financial Results
11. Sangamo BioSciences Announces Fourth Quarter and Full Year 2010 Conference Call and Webcast
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/30/2016)... ... November 30, 2016 , ... Energetiq ... applications, introduces the 5th generation, ultra-bright, Laser-Driven Light Source, the EQ-77, at the ... (LDLS™) technology, the EQ-77 offers higher radiance and irradiance from a truly broadband ...
(Date:11/30/2016)... Carolina (PRWEB) , ... November 30, 2016 , ... On ... names and symbols for four elements: nihonium (Nh), moscovium (Mc), tennessine (Ts), and ... period of public review, the names earlier proposed by the discoverers have been approved ...
(Date:11/30/2016)... Toronto, ON (PRWEB) , ... November 30, 2016 ... ... focused on discovery and development of precision treatments for neurodegenerative diseases, today announced ... disease (AD) (announced on November 3, 2016) blocked propagation of toxic, prion-like forms ...
(Date:11/30/2016)... -- Teil einer Investition von 5 Millionen ... ... Aptuit LLC hat heute bekannt gegeben, ... neuartige Substanzen haben die Prüfsammlung auf über 400.000 erhöht. ... Entdeckungsfähigkeiten des Unternehmens zu erweitern. Die Ausweitung, die durch ...
Breaking Biology Technology:
(Date:11/24/2016)... -- Cercacor today introduced Ember TM Sport Premium ... measure hemoglobin, Oxygen Content, Oxygen Saturation, Perfusion Index, ... approximately 30 seconds. Smaller than a smartphone, using only ... key data about their bodies to help monitor these ... Hemoglobin carries oxygen to muscles. When hemoglobin and ...
(Date:11/22/2016)... 22, 2016   MedNet Solutions , an innovative ... of clinical research, is pleased to announce that the ... and Life Sciences Awards as "Most Outstanding in ... unprecedented year of recognition and growth for MedNet, which ... years. iMedNet ™ , MedNet,s ...
(Date:11/19/2016)... Nov. 18, 2016 Securus Technologies, a leading ... public safety, investigation, corrections and monitoring, announced today that ... ICSolutions, to have an independent technology judge determine who ... modern high tech/sophisticated telephone calling platform, and the best ... they do most of what we do – which ...
Breaking Biology News(10 mins):